Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II DCF plus nivolumab for unresectable advanced esophageal cancer
jRCTs051240130Phase 2Active, not recruiting
- Start
- Oct 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab, docetaxel, cisplatin and fluorouracil in esophageal cancer. Primary endpoint: Overall Response Rate. Started Oct 2024; status: active, not recruiting.
02
Drugs
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on jRCTs051240130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051240130.